Evogene (Israel) Performance
| EVGN Stock | ILA 241.10 15.70 6.11% |
The firm shows a Beta (market volatility) of -0.87, which means possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Evogene are expected to decrease slowly. On the other hand, during market turmoil, Evogene is expected to outperform it slightly. Evogene has an expected return of -0.38%. Please make sure to confirm Evogene total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Evogene performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Evogene has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 46.2 M | |
| Total Cashflows From Investing Activities | -20.6 M |
Evogene |
Evogene Relative Risk vs. Return Landscape
If you would invest 30,730 in Evogene on January 20, 2024 and sell it today you would lose (6,620) from holding Evogene or give up 21.54% of portfolio value over 90 days. Evogene is generating negative expected returns and assumes 4.155% volatility on return distribution over the 90 days horizon. Simply put, 36% of stocks are less volatile than Evogene, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Evogene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evogene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evogene, and traders can use it to determine the average amount a Evogene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0926
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EVGN |
Estimated Market Risk
| 4.16 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Evogene is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evogene by adding Evogene to a well-diversified portfolio.
Evogene Fundamentals Growth
Evogene Stock prices reflect investors' perceptions of the future prospects and financial health of Evogene, and Evogene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evogene Stock performance.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K | |||
| EBITDA | (26.78 M) | |||
| Cash And Equivalents | 65.36 M | |||
| Cash Per Share | 1.61 X | |||
| Total Debt | 2.39 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.74 X | |||
| Cash Flow From Operations | (24.72 M) | |||
| Earnings Per Share | (0.72) X | |||
| Total Asset | 76.3 M | |||
| Retained Earnings | (90 M) | |||
| Current Asset | 95 M | |||
| Current Liabilities | 6 M | |||
About Evogene Performance
To evaluate Evogene Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Evogene generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Evogene Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Evogene market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Evogene's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people.Things to note about Evogene performance evaluation
Checking the ongoing alerts about Evogene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evogene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evogene generated a negative expected return over the last 90 days | |
| Evogene has high historical volatility and very poor performance | |
| The company reported the revenue of 930 K. Net Loss for the year was (27.79 M) with profit before overhead, payroll, taxes, and interest of 163 K. | |
| Evogene has accumulated about 65.36 M in cash with (24.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. |
- Analyzing Evogene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evogene's stock is overvalued or undervalued compared to its peers.
- Examining Evogene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evogene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evogene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evogene's stock. These opinions can provide insight into Evogene's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |